Literature DB >> 27345018

Mortality and Causes of Death in Patients With Osteogenesis Imperfecta: A Register-Based Nationwide Cohort Study.

Lars Folkestad1,2,3, Jannie Dahl Hald4, Vladimir Canudas-Romo5, Jeppe Gram3, Anne Pernille Hermann1, Bente Langdahl4, Bo Abrahamsen2,6,7, Kim Brixen2.   

Abstract

Osteogenesis imperfecta (OI) is a hereditary connective tissue disease that causes frequent fractures. Little is known about causes of death and length of survival in OI. The objective of this work was to calculate the risk and cause of death, and the median survival time in patients with OI. This study was a Danish nationwide, population-based and register-based cohort study. We used National Patient Register data from 1977 until 2013 with complete long-term follow-up. Participants comprised all patients registered with the diagnosis of OI from 1977 until 2013, and a reference population matched five to one to the OI cohort. We calculated hazard ratios for all-cause mortality and subhazard ratios for cause-specific mortality in a comparison of the OI cohort and the reference population. We also calculated all-cause mortality hazard ratios for males, females, and age groups (0 to 17.99 years, 18.00 to 34.99 years, 35.00 to 54.99 years, 55.00 to 74.99 years, and >75 years). We identified 687 cases of OI (379 women) and included 3435 reference persons (1895 women). A total of 112 patients with OI and 257 persons in the reference population died during the observation period. The all-cause mortality hazard ratio between the OI cohort and the reference population was 2.90. The median survival time for males with OI was 72.4 years, compared to 81.9 in the reference population. The median survival time for females with OI was 77.4 years, compared to 84.5 years in the reference population. Patients with OI had a higher risk of death from respiratory diseases, gastrointestinal diseases, and trauma. We were limited by the lack of clinical information about phenotype and genotype of the included patients. Patients with OI had a higher mortality rate throughout their life compared to the general population.
© 2016 American Society for Bone and Mineral Research. © 2016 American Society for Bone and Mineral Research.

Entities:  

Keywords:  CAUSES OF DEATH; COLLAGEN DEFECTS; OSTEOGENESIS IMPERFECTA; RARE BONE DISORDERS; REGISTER-BASED RESEARCH

Mesh:

Year:  2016        PMID: 27345018     DOI: 10.1002/jbmr.2895

Source DB:  PubMed          Journal:  J Bone Miner Res        ISSN: 0884-0431            Impact factor:   6.741


  28 in total

1.  Impact of fracture characteristics and disease-specific complications on health-related quality of life in osteogenesis imperfecta.

Authors:  Masaki Matsushita; Kenichi Mishima; Satoshi Yamashita; Nobuhiko Haga; Sayaka Fujiwara; Keiichi Ozono; Takuo Kubota; Taichi Kitaoka; Naoki Ishiguro; Hiroshi Kitoh
Journal:  J Bone Miner Metab       Date:  2019-08-13       Impact factor: 2.626

2.  Dental and craniofacial defects in the Crtap-/- mouse model of osteogenesis imperfecta type VII.

Authors:  He Xu; Sydney A Lenhart; Emily Y Chu; Michael B Chavez; Helen F Wimer; Milena Dimori; Martha J Somerman; Roy Morello; Brian L Foster; Nan E Hatch
Journal:  Dev Dyn       Date:  2020-03-12       Impact factor: 3.780

3.  Respiratory defects in the CrtapKO mouse model of osteogenesis imperfecta.

Authors:  Milena Dimori; Melissa E Heard-Lipsmeyer; Stephanie D Byrum; Samuel G Mackintosh; Richard C Kurten; John L Carroll; Roy Morello
Journal:  Am J Physiol Lung Cell Mol Physiol       Date:  2020-02-05       Impact factor: 5.464

4.  An Official American Thoracic Society Workshop Report: Translational Research in Rare Respiratory Diseases.

Authors:  Arnold S Kristof; Basil J Petrof; Qutayba Hamid; Martin Kolb; Jennifer S Landry; Alex MacKenzie; Francis X McCormack; Inga J Murawski; Joel Moss; Frank Rauch; Ivan O Rosas; Adam J Shapiro; Benjamin M Smith; David Y Thomas; Bruce C Trapnell; Lisa R Young; Maimoona A Zariwala
Journal:  Ann Am Thorac Soc       Date:  2017-08

Review 5.  Osteogenesis imperfecta: an update on clinical features and therapies.

Authors:  Ronit Marom; Brien M Rabenhorst; Roy Morello
Journal:  Eur J Endocrinol       Date:  2020-10       Impact factor: 6.664

6.  Pulmonary and diaphragmatic pathology in collagen type I α1 mutant mice with osteogenesis imperfecta.

Authors:  Carolyn J Baglole; Feng Liang; Hussein Traboulsi; Angela Rico de Souza; Christian Giordano; Josephine T Tauer; Frank Rauch; Basil J Petrof
Journal:  Pediatr Res       Date:  2018-05-09       Impact factor: 3.756

7.  A multicenter study to evaluate pulmonary function in osteogenesis imperfecta.

Authors:  Allison Tam; Shan Chen; Evan Schauer; Ingo Grafe; Venkata Bandi; Jay R Shapiro; Robert D Steiner; Peter A Smith; Michael B Bober; Tracy Hart; David Cuthbertson; Jeffrey Krischer; Mary Mullins; Peter H Byers; Robert A Sandhaus; Michaela Durigova; Francis H Glorieux; Frank Rauch; Vernon Reid Sutton; Brendan Lee; Eric T Rush; Sandesh C S Nagamani
Journal:  Clin Genet       Date:  2018-09-24       Impact factor: 4.438

8.  Obstructive Constipation in Two Patients With Severe Osteogenesis Imperfecta and Acetabular Protrusio.

Authors:  Erin Stockwell; Maegen Wallace
Journal:  J Am Acad Orthop Surg Glob Res Rev       Date:  2022-01-04

Review 9.  Osteogenesis imperfecta and therapeutics.

Authors:  Roy Morello
Journal:  Matrix Biol       Date:  2018-03-11       Impact factor: 11.583

Review 10.  Osteogenesis Imperfecta: Mechanisms and Signaling Pathways Connecting Classical and Rare OI Types.

Authors:  Milena Jovanovic; Gali Guterman-Ram; Joan C Marini
Journal:  Endocr Rev       Date:  2022-01-12       Impact factor: 19.871

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.